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Abstract The aim of this case study was to examine the
efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin)
and an a-glucosidase inhibitor (miglitol) when added to
ongoing insulin treatment in patients with type 2 diabetes
mellitus. Continuous glucose monitoring was performed in
four Japanese insulin-treated inpatients with type 2 diabe-
tes. Baseline data were collected on day 1. Miglitol was
administered on days 2 and 3. On day 4, miglitol and
anagliptin were coadministered before breakfast. On days
1, 3, and 5, blood was drawn for plasma glucose, serum
C-peptide, plasma glucagon, total and active glucagon-like
peptide-1 (GLP-1), and total and active glucose-dependent
insulinotropic peptide (GIP) measurements. Coadminis-
tration of anagliptin with miglitol resulted in additional
improvements in glycemic control over the entire day in
three of the four patients. The C-peptide, glucagon, and
total and active GLP-1 and GIP responded differently to
the medications for each patient, suggesting interindividual
differences in hormonal responses, which may be compli-
cated by multifactorial effects.
Key Points
Administration of miglitol to four patients with type
2 diabetes receiving ongoing insulin treatment
showed beneficial effects on postprandial
hyperglycemia.
Based on the continuous glucose monitoring results,
the coadministration of anagliptin with miglitol
resulted in additional improvements in glycemic
control in three of the patients.
C-peptide, glucagon, and total and active glucagon-
like peptide-1 and glucose-dependent insulinotropic
peptide responded differently to the study
medications for each patient.
1 Introduction
Dipeptidyl peptidase-4 (DPP-4) inhibitors, by inhibiting
DPP-4 enzymatic activity, increase active glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) levels and improve hyperglycemia in a
glucose-dependent manner by increasing serum insulin and
decreasing serum glucagon levels in diabetic patients [1–6].
Alpha-glucosidase inhibitors (a-GIs), another type of
oral antidiabetic drug, also attenuate postprandial blood
glucose fluctuations by delaying the absorption of digested
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carbohydrates from the small intestine [7–9]. Considering
the different mechanisms of DPP-4 inhibitors and a-GIs,
their use in combination therapy is promising for improv-
ing glycemic control [10, 11]. The present case study
aimed at examining the efficacy, through the use of a
continuous glucose monitoring system (CGMS) [12–14]
and hormone measurements, of a DPP-4 inhibitor (anag-
liptin) [15], and an a-GI (miglitol) when added to ongoing
insulin treatment in patients with type 2 diabetes mellitus.
2 Case Presentation and Intervention
The baseline characteristics of the four Japanese inpatients
with type 2 diabetes in this study are summarized in
Table 1. The study protocol was approved by the Ethics
Committee of the National Center for Global Health and
Medicine (NCGM), and written informed consent was
obtained from each subject. The study was conducted in
accordance with the ethical principles stated in the Dec-
laration of Helsinki and Guidelines for Good Pharmaco-
epidemiology Practice. All patients were admitted to the
diabetes ward at the NCGM and equipped with a CGMS
device (Medtronic MiniMed, CGMS-GOLD, Minneapolis,
MN, USA). Prior to study initiation, oral medications that
might affect the results of the study, such as a-GIs or gli-
nides, were discontinued for at least 5 days. A once-daily
injection of insulin glargine was continued for all patients
throughout the study without changing the dosage and
timing of injections (Table 1). The first blood samples, as
for baseline data, were collected on day 1. Subsequently,
miglitol (50 mg three times a day, just before each meal)
was administered on days 2 and 3. On days 4 and 5,
anagliptin (100 mg/day) was given before breakfast, in
addition to miglitol. Blood samples were collected on the
first, third, and fifth days of the study. Measurements of
plasma glucose, serum C-peptide, plasma glucagon, total
and active GLP-1, and total and active GIP levels were
conducted using blood samples that were drawn at five
time points (0, 15, 30, 60, and 120 min) after breakfast
following a 14-h overnight fast. Active GLP-1 concentra-
tions were measured using an enzyme-linked immunosor-
bent assay (ELISA) kit (Millipore Corp., Billerica, MA,
USA) with solid-phase extraction [16]. Total GLP-1 con-
centrations were measured using a Total GLP-1 (ver. 2)
Assay Kit with an electrochemiluminescence (ECL)
method (Meso Scale Discovery, Rockville, MD, USA).
Active GIP1–42 and inactive GIP3–42 were simultaneously
measured using nanoflow liquid chromatography tandem
mass spectrometry (LC–MS/MS) [17]. Total GIP concen-
tration was calculated as the sum of GIP1–42 and GIP3–42
concentrations. All sample measurements, except those for
total and active GIP, were performed by Mitsubishi
Chemical Medience Corporation (Tokyo, Japan). Total and
active GIP were measured by Sanwa Kagaku Kenkyusyo
Co., Ltd (Aichi, Japan). Serum C-peptide levels were
measured using a chemiluminescent immunoassay (CLIA),
and plasma glucagon was measured using a double-anti-
body radioimmunoassay (RIA). The area under the curve
(AUC) values for these hormones after meal ingestion were
calculated using the trapezoidal rule.
3 Outcomes
Figure 1 shows the representative CGM results of each
patient. In case 1, the glucose levels and fluctuations after
miglitol administration were not remarkably attenuated but
were attenuated when miglitol and anagliptin were coad-
ministered. In case 2, the glucose levels and fluctuations
were not remarkably attenuated even after the administra-
tion of miglitol alone or coadministration of miglitol and
Table 1 Patient characteristics
Characteristic Case 1 Case 2 Case 3 Case 4
Age (years) 63 80 77 83
Sex Male Male Male Female
BMI (kg/m2) 26.2 26.5 22.1 24.8
Diabetes duration (years) 8 15 22 8
HbA1c (%) 7.1 8.0 7.7 8.7
24-h urinary C-peptide (lg/day) 45.2 36.4 9.7 59.8
OAD use before the study Metformin a-GI ? glinide a-GI None
Insulin use before the study Ins L ? Ins G Ins G Ins L ? Ins G Ins G
OAD use during the study Metformin None None None
Dosage and timing of insulin injection
during the study
Ins G (10 units) before
bedtime
Ins G (5 units) before
breakfast
Ins G (5 units) before
lunch
Ins G (5 units) before
bedtime
BMI body mass index, HbA1c glycosylated hemoglobin, OAD oral antidiabetic drug, a-GI a-glucosidase inhibitor, Ins L insulin lispro, Ins G
insulin glargine
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Fig. 1 Continuous glucose monitoring (CGM) results for cases 1–4 under the conditions of insulin administration, coadministration of insulin
and miglitol, and coadministration of insulin, miglitol, and anagliptin
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anagliptin. In cases 3 and 4, the glucose levels and fluc-
tuations after miglitol administration were attenuated, and
this attenuation was even more pronounced with the
combination of miglitol and anagliptin. The accuracy of
these measurements was reflected in the mean and standard
deviation (SD) values of the CGM measurements
(Table 2).
The time-course levels of plasma glucose, serum
C-peptide, plasma glucagon, total and active GLP-1, and
total and active GIP and the AUC values for these hor-
mones for up to 120 min after meal ingestion are sum-
marized in Supplementary Figures 2–5 and Table 3. Under
the fixed dosage and timing of the insulin injection, migl-
itol administration attenuated the postprandial increments
in plasma glucose levels in all of the patients. When
anagliptin was coadministered with miglitol, further
attenuation of postprandial increments in glucose was
observed in case 1, but no remarkable changes in post-
prandial glucose levels were observed in the other patients.
Miglitol administration attenuated the postprandial incre-
ments in C-peptide levels in all of the patients. When
anagliptin was coadministered with miglitol, compared
with the sole administration of miglitol, no remarkable
changes in postprandial C-peptide levels were observed in
cases 1 and 2, but slight increases were observed in cases 3
and 4 although the C-peptide levels in cases 3 and 4 were
much lower than in the other patients. Miglitol adminis-
tration had no observable effect on blood glucagon levels
after meal ingestion in all patients except case 1. When
anagliptin was administered in addition to miglitol, com-
pared to miglitol alone, no remarkable changes in glucagon
levels were observed in cases 2 and 3, but a reduction in
glucagon levels was observed in cases 1 and 4.
Miglitol administration decreased active GLP-1 levels in
cases 1 and 2, but not in cases 3 and 4. However, when
anagliptin was administered in addition to miglitol, all of
the patients showed increased active GLP-1 levels com-
pared to when miglitol alone was added. The AUC values
for active GLP-1 with the coadministration of miglitol and
anagliptin tended to be larger than the AUC values for
active GLP-1 when miglitol alone was added (p = 0.07;
Wilcoxon signed-rank test). Miglitol administration
showed remarkable reductions in active GIP levels in all
patients. Compared to when miglitol alone was added,
coadministration of miglitol and anagliptin showed higher
active GIP levels in all patients, with varying patterns. The
active:total GLP-1 ratio and active:total GIP ratio in each
patient are shown in Supplementary Figures 6 and 7,
respectively. Miglitol administration showed lower or at
least similar active:total GLP-1 ratios and active:total GIP
ratios in all patients, whereas coadministration of miglitol
and anagliptin showed remarkably higher active:total GLP-
1 ratios and active:total GIP ratios in all patients.
4 Discussion
In the present study, administration of miglitol to four
patients with type 2 diabetes receiving ongoing insulin
treatment showed beneficial effects on postprandial
hyperglycemia. Based on the CGM results, the coadmin-
istration of anagliptin with miglitol resulted in additional
improvements in glycemic control over the entire day in
three of the patients, including lower glucose levels and
attenuated glucose fluctuations. In addition, administration
of only miglitol or in combination with anagliptin reduced
postprandial C-peptide levels in all patients we studied,
which might be explained by the associated decrease in
blood glucose levels. The reason underlying the lack of a
further effect on glycemic control with anagliptin co-
administration in case 2 is not clear. A previous study
conducted in Japanese patients with type 2 diabetes indi-
cated that treatment with a different DPP-4 inhibitor, si-
tagliptin, lowered glycosylated hemoglobin (HbA1c)
levels, especially in those with higher baseline HbA1c
levels, lower body mass indices (BMIs), and shorter
durations of diabetes [18]. Therefore, the combination of a
high HbA1c level, relatively high BMI, and long history of
diabetes in case 2 may have affected the efficacy of
anagliptin in this patient to some extent.
Regarding glucagon levels, the effect of miglitol-only
administration was varied; however, when anagliptin was
coadministered with miglitol, all of the patients, except
case 2, showed a tendency for suppressed glucagon
secretion. Theoretically, DPP-4 inhibitors, including
anagliptin, increase GLP-1 levels, and GLP-1 lowers glu-
cose levels not only by its potent insulinotropic action but
also by its ability to suppress glucagon secretion [19–21]. It
remains uncertain and controversial whether GLP-1
directly suppresses glucagon release by binding to GLP-1
Table 2 24-h Glucose levels
measured by continuous glucose
monitoring (CGM)
Values are expressed as
mean ± SD
Treatment Glucose level (mg/dL)
Case 1 Case 2 Case 3 Case 4
Insulin alone 176 ± 36 189 ± 42 234 ± 91 261 ± 37
Insulin ? miglitol 184 ± 30 216 ± 52 165 ± 36 220 ± 26
Insulin ? miglitol ? anagliptin 137 ± 20 208 ± 37 162 ± 27 198 ± 16
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receptors expressed on the alpha cell [19, 22]. Indirectly,
other intraislet paracrine factors, including insulin [23, 24],
somatostatin [19, 25, 26], c-aminobutyric acid (GABA)
[27], and zinc ions (Zn) [28], are considered to modulate
glucagon secretion. In addition, a recent report suggested
that increased portal GLP-1 levels activate brain-derived
neurotrophic factor (BDNF) and BDNF modulates gluca-
gon secretion from pancreatic a cells via the central and
peripheral nervous systems [29].
In patients with diabetes, miglitol is also reported to
induce enhanced and prolonged GLP-1 release after meal
ingestion [30–37]. A possible mechanism may be increased
exposure of nutrients to the distal small intestine, where
L-cells are located [32, 34–36]. To confirm these results,
we previously studied postprandial active GLP-1 levels in
patients with type 2 diabetes treated with or without insulin
and found that miglitol administration increased active
GLP-1 levels in some, but not all, patients [10, 11]. The
effect of miglitol administration in the present study
resulted in varying total or active GLP-1 levels in each
patient, but no typical pattern was observed. As we
expected, coadministration of miglitol and anagliptin
showed increased postprandial active GLP-1 levels in all
patients of various magnitudes, reflecting the pharmaco-
logic effect of anagliptin as a DPP-4 inhibitor. Despite
increased active GLP-1 levels, an increase in total GLP-1
levels was not observed in all patients.
Miglitol administration is reported to decrease GIP
levels, possibly via inhibited glucose absorption in the
proximal small intestine [34]. Our results are consistent
with this theory. Compared to miglitol administration
alone, the coadministration of miglitol and anagliptin
showed increased active GIP levels in all of our patients,
reflecting the pharmacologic effect of anagliptin as a DPP-
4 inhibitor; however, there was a decrease in total GIP
levels in all patients, except case 1. As previously sug-
gested, this phenomenon may be explained by a feedback
inhibitory mechanism; the elevated concentrations of
endogenous biologic active (intact) forms of the incretins
may themselves restrict further secretion from the K- and
L-cells [5, 37].
Table 3 Area under the curve





Parameter Case 1 Case 2 Case 3 Case 4
Glucose AUC (103 9 mg/dL120 min)
Insulin 22.2 31.6 23.8 33.9
Insulin ? miglitol 18.9 24.4 14.7 22.2
Insulin ? miglitol ? anagliptin 15.3 24.0 14.6 25.8
C-peptide AUC (nmol/L120 min)
Insulin 132.4 109.5 35.5 67.3
Insulin ? miglitol 93.6 86.1 16.9 42.5
Insulin ? miglitol ? anagliptin 92.1 88.6 24.6 61.3
Glucagon AUC (103 9 ng/L120 min)
Insulin 17.5 17.3 12.4 11.9
Insulin ? miglitol 15.4 16.8 13.0 12.3
Insulin ? miglitol ? anagliptin 13.7 18.4 11.8 10.8
Total GLP-1 (102 9 pmol/L120 min)
Insulin 26.8 29.9 7.3 14.4
Insulin ? miglitol 21.4 19.8 11.6 16.9
Insulin ? miglitol ? anagliptin 22.1 29.3 9.9 17.0
Active GLP-1 (102 9 pmol/L120 min)
Insulin 5.1 3.5 1.4 3.2
Insulin ? miglitol 3.1 1.9 1.4 3.6
Insulin ? miglitol ? anagliptin 8.7 10.7 2.5 6.8
Total GIP (102 9 pmoL/L120 min)
Insulin 278.6 318.2 131.7 73.0
Insulin ? miglitol 92.0 120.5 58.6 61.6
Insulin ? miglitol ? anagliptin 150.7 73.6 28.6 37.7
Active GIP (102 9 pmol/L120 min)
Insulin 109.6 60.0 31.9 31.0
Insulin ? miglitol 19.2 24.2 8.4 8.1
Insulin ? miglitol ? anagliptin 97.5 44.0 9.8 18.1
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In cases 1 and 2, both total and active GIP levels were
higher than in the other patients, even before anagliptin
administration. The BMIs of these patients were also higher
than the other patients. It is well known that GIP promotes the
efficient storage of ingested fat and directly links overnu-
trition to obesity [38–40]. Furthermore, recent research
suggests that GIP receptor antagonists may offer a new
therapeutic option for obesity in diabetes [41]. As we only
examined four patients, our results do not necessarily gen-
eralize to the majority of the patients with type 2 diabetes.
Therefore, further studies with larger samples are needed.
5 Conclusion
Through the use of CGMS, we determined that a combi-
nation of a-GI, miglitol, and a DPP-4 inhibitor, anagliptin,
was effective in reducing glucose fluctuations and stabi-
lizing postprandial blood glucose levels in three of the four
patients. Furthermore, C-peptide, glucagon, and total and
active GLP-1 and GIP responded differently to the study
medications for each patient, suggesting that hormonal
responses to these drugs differ among individuals and may
be complicated by multifactorial effects. Another larger
study is needed to confirm the associations observed in our
patients.
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